Search

Your search keyword '"Oran, Betul"' showing total 1,220 results
Start Over Author "Oran, Betul"
1,220 results on '"Oran, Betul"'

201. MPN-188: Myeloablative Fludarabine and Busulfan Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors

Author

Joseph, Jacinth, primary, Milton, Denái, additional, Al-Atrash, Gheath, additional, Alousi, Amin, additional, Bashir, Qaiser, additional, Daher, May, additional, Im, Jin, additional, Mehta, Rohtesh, additional, Olson, Amanda, additional, Oran, Betul, additional, Saini, Neeraj, additional, Srour, Samer, additional, Bose, Prithviraj, additional, Pemmaraju, Naveen, additional, Verstovsek, Srdan, additional, Andersson, Borje, additional, Champlin, Richard, additional, and Popat, Uday, additional

Published
2020
Full Text
View/download PDF

202. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial

Author

Popat, Uday, primary, Mehta, Rohtesh S., additional, Bassett, Roland, additional, Kongtim, Piyanuch, additional, Chen, Julianne, additional, Alousi, Amin M., additional, Anderlini, Paolo, additional, Ciurea, Stefan, additional, Hosing, Chitra, additional, Jones, Roy, additional, Kebriaei, Partow, additional, Khouri, Issa, additional, Lindsay, Richard, additional, Nieto, Yago, additional, Olson, Amanda, additional, Oran, Betul, additional, Qazilbash, Muzaffar H., additional, Rondon, Gabriela, additional, Shpall, Elizabeth J., additional, Verstovsek, Srdan, additional, Andersson, Borje S., additional, and Champlin, Richard E., additional

Published
2020
Full Text
View/download PDF

203. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients

Author

Abudayyeh, Ala, primary, Lin, Heather, additional, Abdelrahim, Maen, additional, Rondon, Gabriela, additional, Andersson, Borje S., additional, Martinez, Charles S., additional, Page, Valda D., additional, Tarrand, Jeffrey J., additional, Kontoyiannis, Dimitrios P., additional, Marin, David, additional, Oran, Betul, additional, Olson, Amanda, additional, Jones, Roy, additional, Popat, Uday, additional, Champlin, Richard E., additional, Chemaly, Roy F., additional, Shpall, Elizabeth J., additional, and Rezvani, Katayoun, additional

Published
2020
Full Text
View/download PDF

204. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

Author

Olson, Amanda L., primary, Saliba, Rima M., additional, Oran, Betul, additional, Chen, Julianne, additional, Alousi, Amin, additional, Ahmed, Sairah, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Seon Im, Jin, additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Mehta, Rohtesh, additional, Nieto, Yago, additional, Parmar, Simrit, additional, Rezvani, Katy, additional, Shah, Nina, additional, Shpall, Elizabeth, additional, Srour, Samer A., additional, Qazilbash, Muzaffar, additional, Andersson, Borje S., additional, Champlin, Richard , additional, and Popat, Uday R., additional

Published
2020
Full Text
View/download PDF

205. Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors.

Author

Joseph, Jacinth, primary, Milton, Denai R., additional, Chen, Julianne, additional, Alatrash, Gheath, additional, Alousi, Amin Majid, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Daher, May, additional, Im, Jin Seon, additional, Mehta, Rohtesh S., additional, Oran, Betul, additional, Olson, Amanda Leigh, additional, Saini, Neeraj, additional, Srour, Samer Ali, additional, Andersson, Borje, additional, Champlin, Richard E., additional, and Popat, Uday R., additional

Published
2020
Full Text
View/download PDF

206. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen

Author

Popat, Uday R., primary, Saliba, Rima M., additional, Mehta, Rohtesh S., additional, Olson, Amanda, additional, Chen, Julianne, additional, Ganesh, Christina, additional, Woodworth, Glenda, additional, McMullin, Becky, additional, Alousi, Amin M., additional, Anderlini, Paolo, additional, Alatrash, Gheath, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra M., additional, Im, Jin Seon, additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Marin, David, additional, Nieto, Yago, additional, Oran, Betul, additional, Saini, Neeraj, additional, Srour, Samer A., additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Molldrem, Jeffrey J., additional, Shpall, Elizabeth J., additional, Andersson, Borje S., additional, and Champlin, Richard E., additional

Published
2020
Full Text
View/download PDF

207. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study

Author

Popat, Uday R., primary, Mehta, Rohtesh S., additional, Bassett, Roland, additional, Olson, Amanda, additional, Chen, Julianne, additional, Ganesh, Christina, additional, Alousi, Amin M., additional, Anderlini, Paolo, additional, Alatrash, Gheath, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra M., additional, Seon Im, Jin, additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Marin, David, additional, Nieto, Yago, additional, Oran, Betul, additional, Saini, Neeraj, additional, Srour, Samer A., additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Molldrem, Jeffrey J., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Andersson, Borje S., additional

Published
2020
Full Text
View/download PDF

208. Conditioning with Busulfan Plus Melphalan (Bu-Mel) Results in More Prolonged Progression-Free Survival (PFS) Versus Melphalan (Mel) Alone before Autologous Stem Cell Transplantation (auto-HCT) in Patients with High-Risk Multiple Myeloma (MM): Long-Term Results of a Randomized, Phase 3 Trial

Author

Bashir, Qaiser, primary, Thall, Peter, additional, Milton, Denai R., additional, Kawedia, Jitesh D., additional, Kebriaei, Partow, additional, Patel, Krina, additional, Andersson, Borje S., additional, Nieto, Yago, additional, Valdez, Ben C., additional, Parmar, Simrit, additional, Rondon, Gabriela, additional, Delgado, Ruby, additional, Hosing, Chitra M., additional, Popat, Uday R., additional, Oran, Betul, additional, Ciurea, Stefan O., additional, Lin, Pei, additional, Weber, Donna, additional, Thomas, Sheeba, additional, Lee, Hans C., additional, Manasanch, Elisabet, additional, Orlowski, Robert Z., additional, Shpall, Elizabeth J., additional, Williams, Loretta, additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2020
Full Text
View/download PDF

209. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation

Author

Saliba, Rima M., primary, Veltri, Lauren, additional, Rondon, Gabriela, additional, Chen, Julianne, additional, Al-Atrash, Gheath, additional, Alousi, Amin, additional, Martinez, Charles, additional, Augustine, LaJerald, additional, Hosing, Chitra M., additional, Oran, Betul, additional, Rezvani, Katayoun, additional, Shpall, Elisabeth J., additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Popat, Uday, additional, Champlin, Richard E., additional, and Ciurea, Stefan O., additional

Published
2020
Full Text
View/download PDF

210. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation

Author

Weisdorf, Daniel, primary, Cooley, Sarah, additional, Wang, Tao, additional, Trachtenberg, Elizabeth, additional, Vierra-Green, Cynthia, additional, Spellman, Stephen, additional, Sees, Jennifer A., additional, Spahn, Ashley, additional, Vogel, Jenny, additional, Fehniger, Todd A., additional, Woolfrey, Ann E., additional, Devine, Steven M., additional, Ross, Maureen, additional, Waller, Edmund K., additional, Sobecks, Ronald M., additional, McGuirk, Joseph, additional, Oran, Betul, additional, Farag, Sherif S., additional, Shore, Tsiporah, additional, Van Besien, Koen, additional, Marsh, Steven G. E., additional, Guethlein, Lisbeth A., additional, Parham, Peter, additional, and Miller, Jeffrey S., additional

Published
2020
Full Text
View/download PDF

211. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

Author

Ciurea, Stefan O., primary, Kongtim, Piyanuch, additional, Varma, Ankur, additional, Rondon, Gabriela, additional, Chen, Julianne, additional, Srour, Samer, additional, Bashir, Qaiser, additional, Alousi, Amin, additional, Mehta, Rohtesh, additional, Oran, Betul, additional, Popat, Uday, additional, Hosing, Chitra, additional, Olson, Amanda, additional, Daver, Naval, additional, Konopleva, Marina, additional, and Champlin, Richard E., additional

Published
2020
Full Text
View/download PDF

212. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission.

Author

Pasvolsky, Oren, Saliba, Rima M., Ledesma, Celina, Popat, Uday R., Alousi, Amin, Olson, Amanda, Oran, Betul, Hosing, Chitra, Bashir, Qaiser, Qazilbash, Muzaffar H., Short, Nicholas J., Ravandi, Farhad, Champlin, Richard, Shpall, Elizabeth J., and Kebriaei, Partow

Published
2023
Full Text
View/download PDF

213. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Author

R. Ramlal, Kehinde Adekola, Partow Kebriaei, E. Jabbour, Issa F. Khouri, Oran Betul, Hagop M. Kantarjian, Jorge E. Cortes, Piyanuch Kongtim, Chitra Hosing, Gabriela Rondon, Sairah Ahmed, Stefan O. Ciurea, A. Jimenez, Richard E. Champlin, Denái R. Milton, U. Popat, and J. Chen

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Transplantation Conditioning, Adolescent, Article, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Child, Aged, Hematology, business.industry, Graft Survival, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, Middle Aged, Protein-Tyrosine Kinases, medicine.disease, Lymphoma, Transplantation, Haematopoiesis, Leukemia, surgical procedures, operative, Child, Preschool, 030220 oncology & carcinogenesis, Immunology, Female, Stem cell, business, Tyrosine kinase, 030215 immunology
Abstract

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Published
2017

214. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

Author

Naval Daver, Piyanuch Kongtim, Nicholas J. Short, Lucia Masarova, Farhad Ravandi, Marina Konopleva, Amanda Olson, Maria C.B. Bittencourt, Partow Kebriaei, Oran Betul, Chitra Hosing, Qaiser Bashir, Uday R. Popat, Samer A. Srour, Stefan O. Ciurea, Gheath Alatrash, Rima M. Saliba, Rohtesh S. Mehta, Elias Jabbour, Amin M. Alousi, Issa F. Khouri, Hagop M. Kantarjian, Richard E. Champlin, and Jorge M. Ramos Perez

Subjects
Oncology, Adult, Male, medicine.medical_specialty, Neoplasm, Residual, Transplantation Conditioning, Cyclophosphamide, Kaplan-Meier Estimate, Disease-Free Survival, Young Adult, Bone Marrow, hemic and lymphatic diseases, Internal medicine, Medicine, Humans, Progression-free survival, Melphalan, Aged, Proportional Hazards Models, Retrospective Studies, business.industry, Hazard ratio, Remission Induction, Myeloid leukemia, Hematology, Middle Aged, medicine.disease, Minimal residual disease, Progression-Free Survival, Transplantation, Leukemia, Leukemia, Myeloid, Acute, surgical procedures, operative, Treatment Outcome, Transplantation, Haploidentical, Female, business, Vidarabine, medicine.drug
Abstract

There have been conflicting results regarding the impact of minimal/measurable disease at transplant on acute myeloid leukemia (AML) outcomes after haploidentical transplantation (haplo-SCT). We assessed the impact of pre-transplant disease status on post-transplant outcomes of 143 patients treated with haplo-SCT using fludarabine-melphalan (FM) conditioning and post-transplant cyclophosphamide (PTCy). With a median follow-up of 29 months, the two-year PFS for all patients was 41%. Compared to patients in complete remission (CR) at transplant, those with active disease (n = 29) and CR with incomplete count recovery (CRi) (n = 39) had worse PFS. They had hazard ratios (HR) of 3.5 (95% CI: 2.05-6.1; P < .001) and 2.3 (95% CI: 1.3-3.9; P = .002), respectively. Among patients who were in CR at transplant, there were no differences in PFS between those who had minimal residual disease (MRD) positive (n = 24), and MRD negative (n = 41) (HR 1.85, 95%CI: 0.9-4.0; P = .1). In multivariable analysis for patients in CR, only age was predictive for outcomes, while MRD status at transplant did not influence the treatment outcomes. Our findings suggest that haplo-SCT with FM conditioning regimen and PTCy-based GVHD prophylaxis has a protective effect, and may potentially abrogate the inferior outcomes of MRD positivity for patients with AML. Patients with positive MRD may benefit from proceeding urgently to a haplo-SCT, as this does not appear to negatively impact transplant outcomes.

Published
2019

215. Busulfan Plus Melphalan versus Melphalan Alone Conditioning Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: An Open-label, Randomized Phase III Trial

Author

Bashir, Qaiser, Thall, Peter F., Milton, Denái R., Fox, Patricia S., Kawedia, Jitesh D, Kebriaei, Partow, Shah, Nina, Patel, Krina, Andersson, Borje S., Nieto, Yago L., Valdez, Ben C., Parmar, Simrit, Rondon, Gabriela, Delgado, Ruby, Hosing, Chitra, Popat, Uday R., Oran, Betul, Ciurea, Stefan O., Lin, Pei, Weber, Donna M., Thomas, Sheeba K., Lee, Hans C., Manasanch, Elisabet E., Orlowski, Robert Z., Williams, Loretta A., Champlin, Richard E., and Qazilbash, Muzaffar H.

Subjects
Adult, Male, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Kaplan-Meier Estimate, Middle Aged, Transplantation, Autologous, Article, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Neoplasm Grading, Multiple Myeloma, Busulfan, Melphalan, Aged
Abstract

BACKGROUND: Retrospective studies suggest that conditioning therapy with busulfan (Bu) plus melphalan (Mel) may result in longer progression-free survival (PFS) compared to Mel alone in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (auto-HCT). We aimed to test this hypothesis in a randomized trial. METHODS: The primary objective of the study was to compare PFS with Bu-Mel to Mel alone conditioning in patients with multiple myeloma. Transplant eligible patients with newly diagnosed multiple myeloma, age ≤ 70-years, with at least stable disease, were randomized between October 2011 and April 2017, 1:1 to receive: 1) Bu-Mel, with a test dose of Bu 32 mg/m(2)followed by pharmacokinetically adjusted doses on days −7, −6, −5, and −4 to achieve target daily area under the curve (AUC) 5000 mmol-minute and Mel 70 mg/m(2)/day on days −2 and −1 (total Mel dose 140 mg/m(2)), or 2) Mel 200 mg/m(2) on day −2. Randomization of this single-center, open-labeled, phase III trial was performed via a Clinical Trial Conduct Website at the University of Texas MD Anderson Cancer Center. The primary analysis was based on 202 treated patients (n=104; n=98) comparing PFS in the two treatment groups. The accrual is complete and final results are presented here. The study is registered with ClinicalTrials.gov, number NCT01413178. FINDINGS: There were no treatment-related mortalities by day 100 in either arm. The incidence of grade II-III mucositis was 74% (77 of 104) with Bu-Mel vs. 14% (14 of 98) with Mel. At day-90 after auto-HCT, 102 (98%) patients given Bu-Mel and 95 (97%) patients given Mel achieved partial response (PR) or better. The median follow up for all patients was 21.9 months (IQR: 12.0-46.9 months). Median PFS was 64.7 months (IQR: 32.9, 64.7 months) with Bu-Mel vs. 43.5 months (IQR: 19.9 months, not estimated) with Mel, with HR=0.53, 95% CI [0.30, 0.91] (p=0.022). In a multivariable regression model, Bu-Mel conditioning was significantly associated with superior PFS. INTERPRETATION: These findings, if confirmed in other ongoing studies, suggest that Bu-Mel may replace Mel alone as the conditioning regimen for auto-HCT in newly diagnosed myeloma patients. FUNDING: The National Institutes of Health (NIH) in part funded the study through MD Anderson's Cancer Center Support Grant (CA016672). The NIH employs no author.

Published
2019

216. 379 - Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial

Author

Popat, Uday R, Mehta, Rohtesh S., Bassett, Roland, Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Hosing, Chitra, Im, Jin Seon, Kebriaei, Partow, Kawedia, Jitesh D, Khouri, Issa F., Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Ramdial, Jeremy, Saini, Neeraj Y, Srour, Samer A, Valdez, Ben C., Rezvani, Katayoun, Qazilbash, Muzaffar H., Kadia, Tapan M, Kantarjian, Hagop, Shpall, Elizabeth J, Champlin, Richard E, and Andersson, Borje S.

Published
2022
Full Text
View/download PDF

217. 96 - Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial

Author

Popat, Uday R, Mehta, Rohtesh S., Bassett, Roland, Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Hosing, Chitra, Im, Jin Seon, Kebriaei, Partow, Kawedia, Jitesh D, Khouri, Issa F., Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Ramdial, Jeremy, Saini, Neeraj Y, Srour, Samer A, Rezvani, Katayoun, Qazilbash, Muzaffar H., Shpall, Elizabeth J, Andersson, Borje S., and Champlin, Richard E

Published
2022
Full Text
View/download PDF

218. 95 - Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial

Author

Popat, Uday R, Mehta, Rohtesh S., Bassett, Roland, Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Hosing, Chitra, Im, Jin Seon, Kebriaei, Partow, Gulbis, Alison M., Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Ramdial, Jeremy, Saini, Neeraj Y, Srour, Samer A, Valdez, Ben C., Rezvani, Katayoun, Qazilbash, Muzaffar H., Kadia, Tapan M, Konopleva, Marina, Shpall, Elizabeth J, Andersson, Borje S., and Champlin, Richard E

Published
2022
Full Text
View/download PDF

219. 91 - Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

Author

Popat, Uday R, Mehta, Rohtesh S., Thall, Peter, Bassett, Roland, Alousi, Amin M., Al-Atrash, Gheath, Bashir, Qaiser, Hosing, Chitra, Im, Jin Seon, Kebriaei, Partow, Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Ramdial, Jeremy, Saini, Neeraj Y, Srour, Samer A, Valdez, Ben C., Rezvani, Katayoun, Qazilbash, Muzaffar H., Daver, Naval, Ravandi, Farhad, Shpall, Elizabeth J, Champlin, Richard E, and Andersson, Borje S.

Published
2022
Full Text
View/download PDF

220. Fludarabine with Myeloablative Timed-Sequential Busulfan in Older Patients: Results of a Randomized Phase II Clinical Trial

Author

Popat, Uday R., Mehta, Rohtesh S., Bassett, Roland, Chen, Julianne, Valdez, Benigno C., Kawedia, Jitesh, Ahmed, Sairah, Alousi, Amin M, Anderlini, Paolo, Al-Atrash, Geath, Bashir, Qaiser, Ciurea, Stefan O., Hosing, Chitra M., Im, Jin S., Jones, Roy, Kebriaei, Partow, Khouri, Issa, Marin, David, Nieto, Yago, Olson, Amanda, Oran, Betul, Parmar, Simrit, Rezvani, Katayoun, Qazilbash, Muzaffar H., Shah, Nina, Srour, Samer A., Shpall, Elizabeth J, Champlin, Richard E., and Andersson, Borje S

Subjects
Adult, Male, Time Factors, Adolescent, Dose-Response Relationship, Drug, Comorbidity, Middle Aged, Article, Young Adult, Treatment Outcome, Hematologic Neoplasms, Humans, Drug Interactions, Female, Child, Busulfan, Vidarabine, Aged
Abstract

Haemopoietic stem-cell transplantation (HCT) conditioning regimens that can reduce risk of relapse without increasing non-relapse mortality are needed. We aimed to test the safety of timed-sequential delivery of low-dose versus high-dose myeloablative busulfan in older patients and patients with comorbidities.This non-stratified, open-label, randomised phase 2 trial was done at The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Patients with haematological cancers aged between 5 and 75 years were eligible to participate in the study. Patients who had HIV or uncontrollable infections were excluded. Eligible patients were randomly assigned (1:1 by a computer-generated programme in block sizes of four) to receive a total intravenous busulfan dose to achieve an area under the curve of 16 000 μmol/min (16K group) or 20 000 μmol/min (20K group) on the basis of pharmacokinetic analysis, plus intravenous fludarabine 40 mg/mBetween April 18, 2012, and Dec 9, 2015, 98 patients were enrolled. 49 patients were randomly assigned to the 16K group and 49 to the 20K group, one of which was removed from the study before starting the intervention. Median age was 60 years (IQR 54-67). 50 (52%) patients had an HCT-specific comorbidity index score of 3 or more, and 41 (42%) had a high or very high Disease Risk Index score. Day 100 non-relapse mortality was 4% (95% CI 0-10) in the 16K group and 6% (0-13) in the 20K group (p=0·65). Infection was the most common grade 3-5 toxicity in both the 20K group (25 [52%] of 48 patients) and the 16K group (24 [49%] of 49 participants). Mucositis (nine [19%] of 48 patients vs three [6%] of 49 patients), idiopathic pneumonia syndrome (nine [19%] of 48 patients vs two [4%] of 49 patients), and culture-negative neutropenic fever (16 [33%] of 48 patients vs eight [16%] of 49 patients) were more common in the 20K group than in the 16K group.Myeloablative doses of busulfan administered in a timed-sequential manner with fludarabine is associated with low non-relapse mortality in older patients and patients with comorbidities. Additional studies are required to show whether this approach can reduce the risk of relapse.Cancer Center Support Grant (US National Cancer Institute, National Institutes of Health).

Published
2018

221. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Author

Issa F. Khouri, Partow Kebriaei, Simrit Parmar, Marina Konopleva, Mithun Vinod Shah, Katayoun Rezvani, Amin M. Alousi, Qaiser Bashir, Oran Betul, Elizabeth J. Shpall, Chitra Hosing, Whitney Wallis, Rima M. Saliba, Stefan O. Ciurea, Sameh Gaballa, Naval Daver, Gabriela Rondon, Farhad Ravandi, Julianne Chen, Jorge E. Cortes, Piyanuch Kongtim, Uday R. Popat, Kai Cao, Richard E. Champlin, and Sairah Ahmed

Subjects
Myeloid, Aging, Transplantation Conditioning, Graft vs Host Disease, Disease, Regenerative Medicine, 0302 clinical medicine, Risk Factors, Stem Cell Research - Nonembryonic - Human, hemic and lymphatic diseases, 2.1 Biological and endogenous factors, Aetiology, Cancer, Pediatric, Leukemia, Incidence (epidemiology), Hazard ratio, Myeloid leukemia, Hematology, Middle Aged, Leukemia, Myeloid, Acute, surgical procedures, operative, Treatment Outcome, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Stem Cell Research - Nonembryonic - Non-Human, Stem cell, Post-transplant cyclophosphamide, medicine.drug, Adult, medicine.medical_specialty, Cyclophosphamide, Childhood Leukemia, Pediatric Cancer, Clinical Sciences, Immunology, Acute, Haploidentical, Article, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, medicine, Humans, Aged, Transplantation, Acute myeloid leukemia, business.industry, Cytogenetics, Evaluation of treatments and therapeutic interventions, Stem Cell Research, Elderly patients, Orphan Drug, Myelodysplastic Syndromes, Transplantation, Haploidentical, business, Myelodysplastic syndrome, Haploidentical stem cell transplant, 030215 immunology
Abstract

Allogeneic stem cell transplantation with HLA-matched donors is increasingly used for older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It remains unclear if haploidentical stem cell transplantation (haploSCT) is a suitable option for older patients with this disease. We analyzed 43 patients with AML/MDS (median age, 61 years) who underwent a haploSCT at our institution. All patients received a fludarabine-melphalan–based reduced-intensity conditioning regimen and post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis. Except for 1 patient who had early death, the remaining 42 patients (98%) engrafted donor cells. The cumulative incidences of grades II to IV and III to IV acute GVHD at 6 months were 35% and 5%, respectively, and chronic GVHD at 2 years was 9%. After a median follow-up of 19 months, 2-year overall survival, progression-free survival (PFS), and relapse incidence were 42%, 42%, and 24%, respectively. Best PFS (74% at 2 years) was seen in patients with intermediate-/good-risk cytogenetics, in first or second remission (hazard ratio, .4; P = .05), and with a younger donor (≤40 years; hazard ratio, .2; P = .01). In conclusion, these data suggest that haploidentical transplantation is safe and effective for older AML/MDS patients. Disease status, cytogenetics, and younger donor age are predictors for improved survival in older patients receiving a haploidentical transplant.

Published
2018

222. Erratum : Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Author

Mathew, Nimitha R, Baumgartner, Francis, Braun, Lukas, O'Sullivan, David, Thomas, Simone, Waterhouse, Miguel, Müller, Tony A, Hanke, Kathrin, Taromi, Sanaz, Apostolova, Petya, Illert, Anna L, Melchinger, Wolfgang, Duquesne, Sandra, Schmitt-Graeff, Annette, Osswald, Lena, Yan, Kai-Li, Weber, Arnim, Tugues, Sonia, Spath, Sabine, Pfeifer, Dietmar, Follo, Marie, Claus, Rainer, Lübbert, Michael, Rummelt, Christoph, Bertz, Hartmut, Wäsch, Ralph, Haag, Johanna, Schmidts, Andrea, Schultheiss, Michael, Bettinger, Dominik, Thimme, Robert, Ullrich, Evelyn, Tanriver, Yakup, Vuong, Giang Lam, Arnold, Renate, Hemmati, Philipp, Wolf, Dominik, Ditschkowski, Markus, Jilg, Cordula, Wilhelm, Konrad, Leiber, Christian, Gerull, Sabine, Halter, Jörg, Lengerke, Claudia, Pabst, Thomas, Schroeder, Thomas, Kobbe, Guido, Rösler, Wolf, Doostkam, Soroush, Meckel, Stephan, Stabla, Kathleen, Metzelder, Stephan K, Halbach, Sebastian, Brummer, Tilman, Hu, Zehan, Dengjel, Joern, Hackanson, Björn, Schmid, Christoph, Holtick, Udo, Scheid, Christof, Spyridonidis, Alexandros, Stölzel, Friedrich, Ordemann, Rainer, Müller, Lutz P, Sicre-de-Fontbrune, Flore, Ihorst, Gabriele, Kuball, Jürgen, Ehlert, Jan E, Feger, Daniel, Wagner, Eva-Maria, Cahn, Jean-Yves, Schnell, Jacqueline, Kuchenbauer, Florian, Bunjes, Donald, Chakraverty, Ronjon, Richardson, Simon, Gill, Saar, Kröger, Nicolaus, Ayuk, Francis, Vago, Luca, Ciceri, Fabio, Müller, Antonia M, Kondo, Takeshi, Teshima, Takanori, Klaeger, Susan, Kuster, Bernhard, Kim, Dennis Dong Hwan, Weisdorf, Daniel, van der Velden, Walter, Dörfel, Daniela, Bethge, Wolfgang, Hilgendorf, Inken, Hochhaus, Andreas, Andrieux, Geoffroy, Börries, Melanie, Busch, Hauke, Magenau, John, Reddy, Pavan, Labopin, Myriam, Antin, Joseph H, Henden, Andrea S, Hill, Geoffrey R, Kennedy, Glen A, Bar, Merav, Sarma, Anita, McLornan, Donal, Mufti, Ghulam, Oran, Betul, Rezvani, Katayoun, Shah, Omid, Negrin, Robert S, Nagler, Arnon, Prinz, Marco, Burchert, Andreas, Neubauer, Andreas, Beelen, Dietrich, Mackensen, Andreas, von Bubnoff, Nikolas, Herr, Wolfgang, Becher, Burkhard, Socié, Gerard, Caligiuri, Michael A, Ruggiero, Eliana, Bonini, Chiara, Häcker, Georg, Duyster, Justus, Finke, Jürgen, Pearce, Erika, Blazar, Bruce R, and Zeiser, Robert

Abstract

This corrects the article DOI: 10.1038/nm.4484.

Published
2018

223. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression

Author

Koller, Paul, primary, Saliba, Rima M., additional, Ledesma, Celina, additional, Rondon, Gabriela, additional, Popat, Uday, additional, Alousi, Amin M., additional, Mehta, Rohtesh S., additional, Oran, Betul, additional, Olson, Amanda L., additional, Hosing, Chitra, additional, Qazilbash, Muzaffar H., additional, Khouri, Issa F., additional, Ciurea, Stefan O., additional, Shpall, Elizabeth J., additional, Jorgensen, Jeffrey L., additional, Wang, Sa A, additional, Jain, Nitin, additional, Jabbour, Elias, additional, Kantarjian, Hagop M., additional, Champlin, Richard E, additional, Konopleva, Marina Y, additional, and Kebriaei, Partow, additional

Published
2019
Full Text
View/download PDF

224. Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma

Author

Mukherjee, Akash, primary, Milton, Denái R., additional, Gulbis, Alison, additional, Ledesma, Celina, additional, Jabbour, Elias, additional, Alousi, Amin M., additional, Bashir, Qaiser, additional, Daher, May, additional, Oran, Betul, additional, Olson, Amanda L., additional, Marin, David, additional, Srour, Samer, additional, Kebriaei, Partow, additional, Mehta, Rohtesh S., additional, Nemeth, Kathie P, additional, Popat, Uday, additional, Im, Jin S, additional, Champlin, Richard E., additional, and Khouri, Issa F., additional

Published
2019
Full Text
View/download PDF

225. Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

Author

Olson, Amanda L., primary, Lin, Ruitao, additional, Bdaiwi, Mustafa, additional, Thall, Peter F, additional, Rafei, Hind, additional, Kaur, Indreshpal, additional, Li, Li, additional, Abueg, Glorette, additional, Timmons, Melissa, additional, Chemaly, Roy, additional, Marin, David, additional, Alousi, Amin M., additional, Ahmed, Sairah, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Kebriaei, Partow, additional, Jones, Roy B, additional, Andersson, Borje S, additional, Oran, Betul, additional, Abuddayeh, Ala, additional, Popat, Uday, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, and Rezvani, Katayoun, additional

Published
2019
Full Text
View/download PDF

226. Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Author

Short, Nicholas J., primary, Rafei, Hind, primary, Daver, Naval G., primary, Hwang, Hyunsoo, primary, Ning, Jing, primary, Cortes, Jorge E., primary, Jorgensen, Jeffrey L., primary, Kadia, Tapan M., primary, DiNardo, Courtney D., primary, Wang, Sa A, primary, Jabbour, Elias, primary, Popat, Uday, primary, Oran, Betul, primary, Konopleva, Marina Y, primary, Garcia-Manero, Guillermo, primary, Borthakur, Gautam M., primary, Bhalla, Kapil N., primary, Issa, Ghayas C., primary, Kantarjian, Hagop M., primary, and Ravandi, Farhad, primary

Published
2019
Full Text
View/download PDF

227. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

Author

Champlin, Richard E., primary, Popat, Uday, primary, Oran, Betul, primary, Ciurea, Stefan O., primary, Kebriaei, Partow, primary, Alousi, Amin M., primary, Alatrash, Gheath, primary, Bashir, Qaiser, primary, Khouri, Issa F., primary, Hosing, Chitra, primary, Anderlini, Paolo, primary, Jones, Roy B, primary, Marin, David, primary, Mehta, Rohtesh, primary, Nieto, Yago, primary, Olson, Amanda L., primary, Qazilbash, Muzaffar H., primary, Rezvani, Katy, primary, Shpall, Elizabeth J., primary, Chen, Julianne, primary, Rondon, Gabriela, primary, McMullin, Becky, primary, Al Jahdhami, Vivian P, primary, Kawedia, Jitesh, primary, Valdez, Benigno C., primary, Ma, Junsheng, primary, Thall, Peter F, primary, and Andersson, Borje S, primary

Published
2019
Full Text
View/download PDF

228. Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL)

Author

Khouri, Issa F., primary, Milton, Denái R., primary, Ledesma, Celina, primary, Nastoupil, Loretta J., primary, Jabbour, Elias, primary, Anderlini, Paolo, primary, Bashir, Qaiser, primary, Ciurea, Stefan O., primary, Daher, May, primary, Fayad, Luis E., primary, Im, Jin S, primary, Iyer, Swaminathan P., primary, Marin, David, primary, Mehta, Rohtesh S., primary, Molldrem, Jeffrey J., primary, Olson, Amanda L., primary, Oran, Betul, primary, Popat, Uday, primary, Qazilbash, Muzaffar, primary, Srour, Samer, primary, Samaniego, Felipe, primary, Rondon, Gabriela, primary, Medeiros, L. Jeffrey, primary, Gulbis, Alison, primary, and Champlin, Richard E, primary

Published
2019
Full Text
View/download PDF

229. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation

Author

Yalniz, Fevzi F., primary, Saliba, Rima M., primary, Yucel, Orhan K., primary, Garcia-Manero, Guillermo, primary, Ramdial, Jeremy, primary, Popat, Uday, primary, Ciurea, Stefan O., primary, Kebriaei, Partow, primary, Alousi, Amin M., primary, Alatrash, Gheath, primary, Bashir, Qaiser, primary, Hosing, Chitra, primary, Marin, David, primary, Mehta, Rohtesh, primary, Olson, Amanda L., primary, Rezvani, Katayoun, primary, Shpall, Elizabeth J., primary, Rondon, Gabriela, primary, Champlin, Richard E., primary, and Oran, Betul, primary

Published
2019
Full Text
View/download PDF

230. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen

Author

Popat, Uday, primary, Saliba, Rima M., additional, Mehta, Rohtesh S., additional, Olson, Amanda L., additional, Chen, Julianne, additional, Ganesh, Christina, additional, Rondon, Gabriela, additional, Woodworth, Glenda, additional, McMullin, Becky, additional, Alousi, Amin M., additional, Anderlini, Paolo, additional, Alatrash, Gheath, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Im, Jin S, additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Marin, David, additional, Nieto, Yago, additional, Oran, Betul, additional, Saini, Neeraj, additional, Srour, Samer, additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Molldrem, Jeffrey J., additional, Shpall, Elizabeth J., additional, Andersson, Borje S, additional, and Champlin, Richard E., additional

Published
2019
Full Text
View/download PDF

231. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study

Author

Popat, Uday, primary, Mehta, Rohtesh S., primary, Bassett, Roland, primary, Olson, Amanda L., primary, Chen, Julianne, primary, Ganesh, Christina, primary, Alousi, Amin M., primary, Anderlini, Paolo, primary, Alatrash, Gheath, primary, Bashir, Qaiser, primary, Ciurea, Stefan O., primary, Hosing, Chitra, primary, Im, Jin S, primary, Kebriaei, Partow, primary, Khouri, Issa F., primary, Marin, David, primary, Nieto, Yago, primary, Oran, Betul, primary, Saini, Neeraj, primary, Srour, Samer, primary, Rezvani, Katayoun, primary, Qazilbash, Muzaffar, primary, Molldrem, Jeffrey J., primary, Shpall, Elizabeth J., primary, Andersson, Borje S, primary, and Champlin, Richard E, primary

Published
2019
Full Text
View/download PDF

232. Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients

Author

Oran, Betul, primary, Champlin, Richard E., primary, Wang, Feng, primary, Jeyakumar, Nikeshan, primary, Garcia-Manero, Guillermo, primary, Kantarjian, Hagop M., primary, Saliba, Rima M., primary, Cao, Kai, primary, Shpall, Elizabeth J., primary, Alousi, Amin M., primary, Mehta, Rohtesh S., primary, Popat, Uday, primary, Futreal, Andy, primary, and Takahashi, Koichi, primary

Published
2019
Full Text
View/download PDF

234. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis

Author

Ciurea, Stefan O., primary, Varma, Ankur, primary, Kongtim, Piyanuch, primary, Srour, Samer, primary, Bashir, Qaiser, primary, Alousi, Amin M., primary, Mehta, Rohtesh S., primary, Oran, Betul, primary, Popat, Uday, primary, Hosing, Chitra, primary, Rondon, Gabriela, primary, Chen, Julianne, primary, Olson, Amanda L., primary, Konopleva, Marina Y, primary, and Champlin, Richard E, primary

Published
2019
Full Text
View/download PDF

236. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

Author

Bashir, Qaiser, primary, Chamoun, Kamal, additional, Milton, Denái R., additional, Khan, Maliha, additional, Ahmed, Sairah, additional, Mehta, Rohtesh, additional, Popat, Uday R., additional, Kebriaei, Partow, additional, Nieto, Yago, additional, Oran, Betul, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Khouri, Isa, additional, Patel, Krina, additional, Manasanch, Elisabet E., additional, Lee, Hans C., additional, Orlowski, Robert Z., additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2019
Full Text
View/download PDF

237. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

Author

Saini, Neeraj Y., primary, Saliba, Rima M., additional, Rondon, Gabriela, additional, Maadani, Farzaneh, additional, Popat, Uday, additional, Hosing, Chitra M., additional, Oran, Betul, additional, Bashir, Qaiser, additional, Olson, Amanda, additional, Nieto, Yago, additional, Alousi, Amin, additional, Kebriaei, Partow, additional, Srour, Samer, additional, Mehta, Rohtesh, additional, Anderlini, Paolo, additional, Shpall, Elizabeth J., additional, Qazilbash, Muzaffar H., additional, Khouri, Issa F., additional, Fayad, Luis, additional, Lee, Hun, additional, Fowler, Nathan, additional, Parmar, Simrit, additional, Westin, Jason, additional, Hagemeister, Fredrick, additional, Champlin, Richard E., additional, and Ciurea, Stefan O., additional

Published
2019
Full Text
View/download PDF

238. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results

Author

Chamoun, Kamal, primary, Milton, Denái R., additional, Ledesma, Celina, additional, Young, Ken H., additional, Jabbour, Elias J., additional, Alatrash, Gheath, additional, Anderlini, Paolo, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Marin, David, additional, Molldrem, Jeffrey J., additional, Olson, Amanda L., additional, Oran, Betul, additional, Popat, Uday R., additional, Rondon, Gabriela, additional, Champlin, Richard E., additional, Gulbis, Alison M., additional, and Khouri, Issa F., additional

Published
2019
Full Text
View/download PDF

239. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission

Author

Rashidi, Armin, primary, Hamadani, Mehdi, additional, Zhang, Mei-Jie, additional, Wang, Hai-Lin, additional, Abdel-Azim, Hisham, additional, Aljurf, Mahmoud, additional, Assal, Amer, additional, Bajel, Ashish, additional, Bashey, Asad, additional, Battiwalla, Minoo, additional, Beitinjaneh, Amer M., additional, Bejanyan, Nelli, additional, Bhatt, Vijaya Raj, additional, Bolaños-Meade, Javier, additional, Byrne, Michael, additional, Cahn, Jean-Yves, additional, Cairo, Mitchell, additional, Ciurea, Stefan, additional, Copelan, Edward, additional, Cutler, Corey, additional, Daly, Andrew, additional, Diaz, Miguel-Angel, additional, Farhadfar, Nosha, additional, Gale, Robert P., additional, Ganguly, Siddhartha, additional, Grunwald, Michael R., additional, Hahn, Theresa, additional, Hashmi, Shahrukh, additional, Hildebrandt, Gerhard C., additional, Holland, H. Kent, additional, Hossain, Nasheed, additional, Kanakry, Christopher G., additional, Kharfan-Dabaja, Mohamed A., additional, Khera, Nandita, additional, Koc, Yener, additional, Lazarus, Hillard M., additional, Lee, Jong-Wook, additional, Maertens, Johan, additional, Martino, Rodrigo, additional, McGuirk, Joseph, additional, Munker, Reinhold, additional, Murthy, Hemant S., additional, Nakamura, Ryotaro, additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Palmisiano, Neil, additional, Patel, Sagar, additional, Pidala, Joseph, additional, Olin, Rebecca, additional, Olsson, Richard F., additional, Oran, Betul, additional, Ringden, Olov, additional, Rizzieri, David, additional, Rowe, Jacob, additional, Savoie, Mary Lynn, additional, Schultz, Kirk R., additional, Seo, Sachiko, additional, Shaffer, Brian C., additional, Singh, Anurag, additional, Solh, Melhem, additional, Stockerl-Goldstein, Keith, additional, Verdonck, Leo F., additional, Wagner, John, additional, Waller, Edmund K., additional, De Lima, Marcos, additional, Sandmaier, Brenda M., additional, Litzow, Mark, additional, Weisdorf, Dan, additional, Romee, Rizwan, additional, and Saber, Wael, additional

Published
2019
Full Text
View/download PDF

240. Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study.

Author

Popat, Uday R., primary, Mehta, Rohtesh S., additional, Bassett, Roland, additional, Olson, Amanda Leigh, additional, Alousi, Amin Majid, additional, Anderlini, Paolo, additional, Alatrash, Gheath, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Marin, David, additional, Nieto, Yago, additional, Oran, Betul, additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Andersson, Borje, additional

Published
2019
Full Text
View/download PDF

241. Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.

Author

Mukherjee, Akash, primary, Milton, Denai R., additional, Jabbour, Elias, additional, Konopleva, Marina, additional, Dinardo, Courtney Denton, additional, Gulbis, Alison, additional, Ravandi, Farhad, additional, Daver, Naval Guastad, additional, Kadia, Tapan M., additional, Oran, Betul, additional, Popat, Uday R., additional, Ciurea, Stefan O., additional, Im, Jin, additional, Kebriaei, Partow, additional, Mehta, Rohtesh S., additional, Kantarjian, Hagop M., additional, Champlin, Richard E., additional, and Khouri, Issa F., additional

Published
2019
Full Text
View/download PDF

242. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

Author

Bashir, Qaiser, primary, Thall, Peter F, additional, Milton, Denái R, additional, Fox, Patricia S, additional, Kawedia, Jitesh D, additional, Kebriaei, Partow, additional, Shah, Nina, additional, Patel, Krina, additional, Andersson, Borje S, additional, Nieto, Yago L, additional, Valdez, Ben C, additional, Parmar, Simrit, additional, Rondon, Gabriela, additional, Delgado, Ruby, additional, Hosing, Chitra, additional, Popat, Uday R, additional, Oran, Betul, additional, Ciurea, Stefan O, additional, Lin, Pei, additional, Weber, Donna M, additional, Thomas, Sheeba K, additional, Lee, Hans C, additional, Manasanch, Elisabet E, additional, Orlowski, Robert Z, additional, Williams, Loretta A, additional, Champlin, Richard E, additional, and Qazilbash, Muzaffar H, additional

Published
2019
Full Text
View/download PDF

243. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant

Author

Ghobadi, Armin, primary, Milton, Denái R., additional, Gowda, Lohith, additional, Rondon, Gabriela, additional, Chemaly, Roy F., additional, Hamdi, Amir, additional, Alousi, Amin, additional, Afrough, Aimaz, additional, Oran, Betul, additional, Ciurea, Stefan, additional, Kebriaei, Partow, additional, Popat, Uday R., additional, Qazilbash, Muzaffar H., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Bashir, Qaiser, additional

Published
2019
Full Text
View/download PDF

244. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial

Author

Mehta, Rohtesh S., primary, Bassett, Roland, additional, Olson, Amanda, additional, Chen, Julianne, additional, Ahmed, Sairah, additional, Alousi, Amin M., additional, Anderlini, Paolo, additional, Al-Atrash, Gheath, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra M., additional, Im, Jin S., additional, Kebriaei, Partow, additional, Khouri, Issa, additional, Marin, David, additional, Molldrem, Jeffrey J., additional, Nieto, Yago, additional, Oran, Betul, additional, Rezvani, Katayoun, additional, Qazilbash, Muzaffar H., additional, Srour, Samer A., additional, Shpall, Elizabeth J., additional, Andersson, Borje S., additional, Champlin, Richard E., additional, and Popat, Uday R., additional

Published
2019
Full Text
View/download PDF

245. Comparison of Tacrolimus and Post-Transplant Cyclophosphamide (PTCy) with Tacrolimus and Methotrexate (Tac/MTX) Gvhd Prophylaxis in Patients with AML Undergoing Transplantation from Matched Related or Unrelated Donors

Author

Popat, Uday R., primary, Saliba, Rima M, additional, Olson, Amanda, additional, Mehta, Rohtesh S., additional, Ahmed, Sairah, additional, Alousi, Amin M., additional, Anderlini, Paolo, additional, Al-Atrash, Gheath, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra M., additional, Im, Jin Seon, additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Marin, David, additional, Molldrem, Jeffrey J, additional, Nieto, Yago, additional, Oran, Betul, additional, Qazilbash, Muzaffar H., additional, Rezvani, Katy, additional, Rondon, Gabriela, additional, Shpall, EJ J., additional, Varma, Ankur, additional, Andersson, Borje S., additional, and Champlin, Richard E., additional

Published
2019
Full Text
View/download PDF

246. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia

Author

Veltri, Lauren, primary, Rezvani, Katayoun, additional, Oran, Betul, additional, Mehta, Rohtesh, additional, Rondon, Gabriela, additional, Kebriaei, Partow, additional, Popat, Uday, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Qazilbash, Muzaffar, additional, Khouri, Issa, additional, Shpall, Elizabeth, additional, Champlin, Richard, additional, and Marin, David, additional

Published
2019
Full Text
View/download PDF

247. Myeloablative Conditioning Using Timed Sequential Busulfan in Older Patients with Acute Myeloid Leukemia: Long Term Results of a Prospective Phase II Clinical Trial

Author

Mehta, Rohtesh S., primary, Bassett, Roland, additional, Olson, Amanda, additional, Chen, Julianne, additional, Ahmed, Sairah, additional, Anderlini, Paolo, additional, Al-Atrash, Gheath, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra M., additional, Im, Jin Seon, additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Marin, David, additional, Nieto, Yago, additional, Oran, Betul, additional, Rezvani, Katy, additional, Qazilbash, Muzaffar H., additional, Srour, Samer A., additional, Molldrem, Jeffrey J, additional, Shpall, EJ J., additional, Andersson, Borje S., additional, Champlin, Richard E., additional, and Popat, Uday R., additional

Published
2019
Full Text
View/download PDF

248. HLA-Matched Sibling Versus Haploidentical Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

Author

Rashidi, Armin, primary, Hamadani, Mehdi, additional, Wang, Hai-Lin, additional, Bolanos, Javier, additional, Lee, Jong Wook, additional, Ciurea, Stefan O., additional, Holland, H. Kent, additional, Koc, Yener, additional, Maertens, Johan A., additional, Stockerl-Goldstein, Keith, additional, Bashey, Asad, additional, Aljurf, Mahmoud, additional, Cutler, Corey, additional, Nakamura, Ryotaro, additional, Oran, Betul, additional, Shaffer, Brian C., additional, Hahn, Theresa E., additional, de Lima, Marcos, additional, Sandmaier, Brenda M., additional, Litzow, Mark R., additional, Weisdorf, Daniel J., additional, Zhang, Mei-Jie, additional, Romee, Rizwan, additional, and Saber, Wael, additional

Published
2019
Full Text
View/download PDF

249. Idiopathic Portal Hypertension Related Refractory Ascites (IPHRA) after Allogeneic Stem Cell Transplant

Author

Varma, Ankur, primary, Abraham, Susan C., additional, Saini, Neeraj, additional, Bashir, Qaiser, additional, Rondon, Gabriela, additional, Srour, Samer A., additional, Mehta, Rohtesh S., additional, Olson, Amanda, additional, Oran, Betul, additional, Hosing, Chitra M., additional, Nieto, Yago, additional, Kebriaei, Partow, additional, Alousi, Amin M., additional, Ahmed, Sairah, additional, Marin, David, additional, Khouri, Issa F., additional, Ciurea, Stefan O., additional, Qazilbash, Muzaffar H., additional, Rezvani, Katy, additional, Shpall, E.J.J., additional, Champlin, Richard E., additional, and Popat, Uday R., additional

Published
2019
Full Text
View/download PDF

250. Influence of the Intensity of the Allogeneic Conditioning Regimen on the Risk of Hemorrhagic Cystitis (HC) in Patients Receiving Post- Transplant Cyclophosphamide (PT-Cy) As Gvhd Prophylaxis

Author

Mukherjee, Akash, primary, Milton, Denai, additional, Ledesma, Celina, additional, Olson, Amanda, additional, Alatrash, Gheath, additional, Anderlini, Paolo, additional, Alousi, Amin M., additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Kebriaei, Partow, additional, Marin, David, additional, Molldrem, Jeffrey J., additional, Oran, Betul, additional, Popat, Uday R., additional, Qazilbash, Muzaffar H., additional, Rondon, Gabriela, additional, Champlin, Richard E., additional, Gulbis, Alison M., additional, and Khouri, Issa F., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results